Journal: Oncotarget

Article Title: Pancreatic cancer-derived exosomes promote tumor metastasis and liver pre-metastatic niche formation

doi: 10.18632/oncotarget.18831

Figure Lengend Snippet: Confocal microscopy (lung, liver, spleen, brain) of PKH67-labeled Panc02 EXO and Panc02-H7 EXO tissue distribution (green) 24 hpi. (A) PKH-67-labeled liposomes served as controls (scale bar=100 μm). Histogram shows exosome tissue distribution quantification (n=5/group). CD45, p-Stat3, and CD11b IF staining in liver sections from controls (left) and mice treated with Panc02 EXOs(middle) or Panc02-H7 EXOs (right) for 12 d without tumor challenge. (B) Histogram shows infiltrating CD45 + cell quantification. FN and α-SMA IF staining in liver sections from controls (top) and mice treated with Panc02 EXOs(middle) or Panc02-H7 EXOs (bottom) for 12 d without tumor challenge. (C) Histogram shows infiltrating α-SMA + hStCs and FN expression quantification(400× magnification; n=5/group). Western blotting analysis showed upregulated S100A8 and S100A9 in livers treated with Panc02-H7-derived exosomes. Histogram shows expression of the three proteins in three groupsas determined by densitometric analysis (n=3/group). (D) Pancreatic cancer-derived exosomes induce MDSC accumulation in peripheral blood. (E) Representative flow cytometric plots (left) and quantification (right) of CD11b + GR1 + MDSCs (n=5/group). *P<0.05, **P<0.01,***P<0.001.

Article Snippet: Primary antibodies against fibronectin (1:100),α-SMA (1:50), S100A8 (1:50), S100A9 (1:50), and F4/80 (1:50) were purchased from Proteintech (Wuhan, China).

Techniques: Confocal Microscopy, Labeling, Liposomes, Staining, Expressing, Western Blot, Derivative Assay

Journal: Oncotarget

Article Title: Pancreatic cancer-derived exosomes promote tumor metastasis and liver pre-metastatic niche formation

doi: 10.18632/oncotarget.18831

Figure Lengend Snippet: IHC analysis and histopathological examination of macrophages (F4/80), hStCs (α-SMA), and neutrophils in liver metastatic niches of naïve mice and mice treated with PBS, Panc02 EXOs, or Panc02-H7 EXOs at 30d post-SOI (arrow shows neutrophils in liver) (A) . Representative histogram shows quantification of F4/80 + macrophages, α-SMA + hStCs, and neutrophils (B) . Identification of FN, S100A8, and S100A9 as inflammatory mediators, and collagen deposition in the liver metastatic niche (C) . Representative histogram shows FN and MTS quantification (D) . Representative histogram shows S100A8 and S100A9 quantification (E) . n=6/group.**P<0.01,***P<0.001.10 fields assessed per sample. FOV, field of view.

Article Snippet: Primary antibodies against fibronectin (1:100),α-SMA (1:50), S100A8 (1:50), S100A9 (1:50), and F4/80 (1:50) were purchased from Proteintech (Wuhan, China).

Techniques:

Journal: Frontiers in Oncology

Article Title: Identification of a Two-Gene ( PML-EPB41 ) Signature With Independent Prognostic Value in Osteosarcoma

doi: 10.3389/fonc.2019.01578

Figure Lengend Snippet: The functional analysis of candidate genes. (A) Visualization for functional enrichment results of 733 candidate genes by Cytoscape software. Each node represents an annotation term. (B) The results of g: profiler functional enrichment with prognostic candidate genes. Horizontal axis above represents annotation terms. Vertical axis represents the value of –log 10 ( p -value). (C) The Kaplan–Meier curves for overall survival of high- and low-risk groups of OSA in the internal training dataset and external validating dataset. The prognostic differences between the two groups in internal training dataset was significant (log-rank test p = 0.0057). (D) ROC of PML-EPB41 signature based on PI in training dataset samples. (E) ROC of PML signature in training dataset samples. (F) ROC of EPB41 signature in training dataset samples.

Article Snippet: The EPB41 antibody (Cat. no. 13014-1-AP), PML antibody (Cat. no. 21041-1-AP) and GAPDH antibody (Cat. no. 60004-1-Ig) were obtained from Proteintech.

Techniques: Functional Assay, Software

Journal: Frontiers in Oncology

Article Title: Identification of a Two-Gene ( PML-EPB41 ) Signature With Independent Prognostic Value in Osteosarcoma

doi: 10.3389/fonc.2019.01578

Figure Lengend Snippet: Result of univariate Cox regression analysis.

Article Snippet: The EPB41 antibody (Cat. no. 13014-1-AP), PML antibody (Cat. no. 21041-1-AP) and GAPDH antibody (Cat. no. 60004-1-Ig) were obtained from Proteintech.

Techniques:

Journal: Frontiers in Oncology

Article Title: Identification of a Two-Gene ( PML-EPB41 ) Signature With Independent Prognostic Value in Osteosarcoma

doi: 10.3389/fonc.2019.01578

Figure Lengend Snippet: Result of multivariate Cox regression analysis.

Article Snippet: The EPB41 antibody (Cat. no. 13014-1-AP), PML antibody (Cat. no. 21041-1-AP) and GAPDH antibody (Cat. no. 60004-1-Ig) were obtained from Proteintech.

Techniques:

Journal: Frontiers in Oncology

Article Title: Identification of a Two-Gene ( PML-EPB41 ) Signature With Independent Prognostic Value in Osteosarcoma

doi: 10.3389/fonc.2019.01578

Figure Lengend Snippet: (A) Relative mRNA expression level of PML and EPB41 in three cell lines are conducted by quantitative polymerase chain reaction. Data are presented as the mean ± SD. * P < 0.05 vs. hFOB1.19. (B) Expression of EPB41 and PML by western blot. Protein levels were statistically evaluated in columns. Measurements were in triplicate and data were presented as the mean ± SD. ** P < 0.01 vs. hFOB1.19.

Article Snippet: The EPB41 antibody (Cat. no. 13014-1-AP), PML antibody (Cat. no. 21041-1-AP) and GAPDH antibody (Cat. no. 60004-1-Ig) were obtained from Proteintech.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot